November 30, 2021 5:16pm

There exist more unknowns than knowns in the sector

Pre-open indication results: 6 HITs, 2 MISS

The Biostage (BSTG) Chronicles: Monday closed down -$0.02 with 2,143 shares traded even with news of a new CEO and Chairman, David Green after Monday’s -$0.40 to $2.00 with 6,025 shares traded.

Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public markets investor to a journalist; it is that your life and your bank account are largely tied to your questioning of price targets.

The Dow closed DOWN -652.22 points (-1.86%); the S&P closed DOWN -88.27 points (-1.90%) while the Nasdaq closed DOWN -245.14 points (-1.55%)

 

Henry’omics:

Indexes tanked Tuesday, as the Dow dived more than 600 points after Fed Chief Powell's comments spurred inflation fears.

  • Saying it’s time to consider speeding up the tapering of the central bank's monthly asset purchases when they meet next month.
  • The Fed will back off of using the word “transitory” to describe the fast pace of price increases, acknowledging the increasing risk of more persistent inflation.

The CBOE volatility index, the VIX fear gauge, was higher at 27.19 on Tuesday after Monday’s 22.96

 

Note: The FDA said it hopes to have information about the effectiveness of current COVID-19 vaccines against Omicron, vaccine companies appeared divided.

  • BioNTech's (BNTX) chief executive said the BioNTech and Pfizer (PFE +2.5%) COVID-19 vaccine will likely offer strong protection against severe disease from the variant, while Moderna's (MRNA) CEO told the Financial Times that COVID-19 shots are unlikely to be as effective against the new variant as they have been previously.
  • MRNA shares fell (-$16.08 or -4.36%) while Regeneron Pharmaceuticals (RGNX) were also under pressure after it said its COVID-19 antibody treatment and other similar drugs could be less effective against Omicron.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Tuesday opened positive at 18 ups/15 downs, 1 flat and 1 acquired, flipped negative at the mid-day at 12/22 and 1 acquired, ending with a positive close of 19 ups/15 downs and 1 acquired;
  • Monday opened negative at 12 ups/20 downs, 2 flat and 1 acquired, stayed negative at the mid-day at 6/27, 1 flat and 1 acquired, ending with a negative close of 4/31 and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “it ain’t over, investors are wary of buying dips as electronic trading contracts and controls share pricing. After a weak aftermarket, expectation is not a strength reality as we are still in a share pricing risk danger zone.” …  https://www.regmedinvestors.com/articles/12203

 

Pre-open indication results: 6 HITs: <Biostage (BSTG -$0.02), Athersys (ATHX +$0.04), Cellectis SA (CLLS +$0.25), CRISPR Therapeutics (CRSP +$1.92), Fate Therapeutics (FATE +$3.24), Sage Therapeutics (SAGE +$0.38)> 2 MISS < Ionis Pharmaceuticals (IONS -$0.95), Verastem (VSTM +$0.08)>

 

 

The Biostage (BSTG) Chronicles: Tuesday closed down again -$0.02 with 2,143 shares traded after Monday closed down -$0.40 to $2.00 with 6,025 shares traded.

  • New CEO and chairman with a personal investment wil do WHAT? He should start with messaging and  a year long drought of question response!
  • NO clinical trial from a one (1) and 3/4-year-old IND and a negligence rejection of reimbursement in a terminal death suit.
  • What’s there to invest in, the “Sword of Damocles” hanging over the companies non-going operations?

 

Key Metric - volume

Sector volume INCREASED with 13 of the 19-upside having higher than the 3-month average volume with INCREASED volume of 7 of 15-downside having higher than the 3-month average volume;

Outstanding upside volume:

  • Athersys (ATHX) with 10.57 m shares traded
  • Sangamo Therapeutics (SGMO) with 2.369 m shares traded

Outstanding downside volume:

  • Adverum Biotechnologies (ADVM) with 5.115 m shares traded
  • Solid Biosciences (SLDB) with 2.473 m shares traded
  • Ionis Pharmaceuticals (IONS) with 2.023 m shares traded

 

There were some serious 52-week lows:

  • XBI reached a 52-week low of 113.69
  • bluebird bio (BLUE) reached a 52-week low of $10.10
  • Adverum Biotechnologies (ADVM) reached a 52-week low of $1.84
  • Applied Genetics Technologies (AGTC) reached a 52-week low of $2.10
  • Sage Therapeutics (SAGE) reached a 52-week low of $37.95
  • Solid Biosciences (SLDB) reached a 52-week low of $1.80
  • Sangamo Therapeutics (SGMO) reached a 52-week low of $7.81
  • Ionis Pharmaceuticals (IONS) reached a 52-week low of $28.45, closing at $27.11

 

Jumping with share pricing momentum (10 of 19):

  • Intellia Therapeutics (NTLA +$3.28 after Monday’s -$1.40),
  • Fate Therapeutics (FATE +$3.24),
  • Alnylam Pharmaceuticals (ALNY +$3.06 after Monday’s -$7.79),
  • CRISPR Therapeutics (CRSP +$1.92)
  • Regenxbio (RGNX +$1.81 after Monday’s -$0.77),
  • Ultragenyx (RARE +$1.52 after Monday’s -$2.78),
  • Editas Medicine (EDIT +$1.40 after Monday’s -$1.11),
  • Chinook Therapeutics (KDNY +$0.40 after Monday’s +$0.23),
  • Sage Therapeutics (SAGE +$0.38 after Monday’s -$0.79)
  • AxoGen (AXGN +$0.34),

Hammered in today’s market (10 of 15):

  • ReNeuron (RENE.L-$2.00 after Monday’s +$1.00),
  • Ionis Pharmaceuticals (IONS -0.95 after Monday’s -$1.60),
  • BioLife Solutions (BLFS -$0.93 after Monday’s -$2.07),
  • uniQure NV (QURE -$0.67),
  • bluebird bio (BLUE -$0.22),
  • Adverum Biotechnologies (ADVM -$0.13),
  • MiMedx (MDXG -$0.13),
  • Homology Medicine (FIXX -$0.12),
  • Vericel (VCEL -$0.10 after Monday’s -$1.00),
  • Applied Genetics Technologies (AGTC -$0.10),

Closing Flat:

  • 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed down -1.18% and XBI closed up +1.06%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +4.23 points or +18.42% at 27.19

 

November, the second month of Q4/21:

Tuesday closed negative with 19 incliners, 15 decliners and 1 acquired

Monday (11/29) closed negative with 3 incliners, 31 decliners and 1 acquired

Friday closed negative with 3 incliners, 29 decliners, 2 flats and 1 acquired

Thursday was Thanksgiving holiday

Wednesday closed positive with 23 incliners, 10 decliners, 1 flat and 1 acquired

Tuesday closed positive with 17 incliners, 16 decliners, 1 flat and 1 acquired

Monday (11/22) closed negative with 6 incliners, 28 decliners and 1 acquired

Friday closed negative with 12 incliners, 22 decliners and 1 acquired

Thursday closed negative with 8 incliners, 25 decliners, 1 flat and 1 acquired

Wednesday closed negative with 6 incliners, 25 decliners, 3 flats and 1 acquired

Tuesday closed negative with 16 incliners, 18 decliners and 1 acquired

Monday (11/15) closed negative with 13 incliners,20 decliners, 2 flats and 1 acquired

Friday closed negative with 12 incliners, 18 decliners, 4 flat and 1 acquired

Thursday closed negative with 15 incliners, 18 decliners, 1 flat and 1 acquired

Wednesday closed negative with 4 incliners, 30 decliners and 1 acquired

Tuesday closed negative with 9 incliners, 24 decliners, 1 flat and 1 acquired

Monday (11/8) closed positive with 29 incliners, 3 decliners, 2 flats and 1 acquired

Friday closed negative with 11 incliners, 19 decliners, 4 flat and 1 acquired

Thursday closed negative with 16 incliners, 17 decliners, 1 flat and 1 acquired

Wednesday closed positive with 28 incliners, 6 decliners and 1 acquired

Tuesday closed positive with 24 incliners, 8 decliners, 2 flats and 1 acquired

Monday (11/1) closed positive with 29 incliners, 3 decliners, 2 flats and 1 acquired

 

The BOTTOM LINE: Ending the month on a solid upside foundation

However, we are also about to enter into TAX SELLING for year’s end!

In any case, I wouldn’t ramp up your exposure at the current levels.

There's also nothing wrong with standing pat after reducing exposure earlier in the month.

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.